CN1328827A - Nanometer silver antimicrobial inflammation-relieving gel for curing prostatitis and its industrial production process - Google Patents

Nanometer silver antimicrobial inflammation-relieving gel for curing prostatitis and its industrial production process Download PDF

Info

Publication number
CN1328827A
CN1328827A CN01129507A CN01129507A CN1328827A CN 1328827 A CN1328827 A CN 1328827A CN 01129507 A CN01129507 A CN 01129507A CN 01129507 A CN01129507 A CN 01129507A CN 1328827 A CN1328827 A CN 1328827A
Authority
CN
China
Prior art keywords
silver
nano
prostatitis
gel
antibacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN01129507A
Other languages
Chinese (zh)
Other versions
CN1169529C (en
Inventor
朱红军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Yuanxing Nano-Pharmaceutical Co., Ltd.
Original Assignee
朱红军
朱骊
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CNB011107677A priority Critical patent/CN1179646C/en
Priority to CN01223000U priority patent/CN2479952Y/en
Application filed by 朱红军, 朱骊 filed Critical 朱红军
Priority to CN01129505A priority patent/CN1328819A/en
Priority to CNB011295074A priority patent/CN1169529C/en
Priority to CNB018231578A priority patent/CN1224479C/en
Priority to PCT/CN2001/001584 priority patent/WO2002090025A1/en
Publication of CN1328827A publication Critical patent/CN1328827A/en
Application granted granted Critical
Publication of CN1169529C publication Critical patent/CN1169529C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/23—Solid substances, e.g. granules, powders, blocks, tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/23—Solid substances, e.g. granules, powders, blocks, tablets
    • A61L2/238—Metals or alloys, e.g. oligodynamic metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B22F1/05—Metallic powder characterised by the size or surface area of the particles
    • B22F1/054—Nanosized particles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F9/00—Making metallic powder or suspensions thereof
    • B22F9/16—Making metallic powder or suspensions thereof using chemical processes
    • B22F9/18—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds
    • B22F9/24—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites

Abstract

The present invention discloses a nanometer silver antibiotical inflammation-relieving gel for curing male prostatitis and relieving pain resulted from senile male organic prostatosis, and for curing internal and external hemorrhoids with excellent therapeutic effect. The said gel contains pharmaceutically acceptable additive and broad-spectrum antibiotical nanometer silver micropowder, and is characterized by that the grain size of nanometer silver is 1-100 nanometers, surface layer is 2-8 nanometers of silver oxide, and its core is element silver.

Description

Nano silver prostatitis antibacterial and anti-inflammatory gel and industrial production process thereof
The invention relates to an antibacterial medicament adopting nano-silver, in particular to a nano-silver prostatitis antibacterial and anti-inflammatory gel, an industrial production process and application thereof.
Prostatitis in men is caused by the prostate being surrounded by a thick lipid layer. Therefore, when the existing drug therapy is applied, the active ingredients of the drug hardly penetrate the lipid layer to reach the focus. Modern medical research shows that the effective medicinal component reaching the focus of the prostate is only 1/1000 dosage, so the treatment effect is poor and the traditional Chinese medicine preparation is a difficult problem in domestic and foreign medical fields. So far, no specific medicine for treating male prostatitis exists in the world.
The invention aims to provide a nano-silver antibacterial anti-inflammatory gel for treating prostatitis.
The second purpose of the invention is to provide an industrial production process of the nano-silver antibacterial and anti-inflammatory gel for treating the prostatitis.
This and other objects of the invention will be further apparent and elucidated by the following detailed description and description.
The nano-silver prostatitis antibacterial and anti-inflammatory gel contains a pharmaceutically acceptable additive and anti-aggregation broad-spectrum antibacterial nano-silver micro powder, wherein the particle size of the nano-silver is 1-100 nanometers, the surface layer is silver oxide of 2-8 nanometers, and the core is elemental silver; the pharmaceutically acceptable additives comprise monomer carriers, surfactants, dispersing agents, transdermal enhancers and the like.
In the nano-silver prostatitis antibacterial and anti-inflammatory gel, the formula of the medicament is as follows (calculated by 10 kg of gel):
A. 200 to 600 g of stearyl alcohol, 2000 to 8000 g of PEG400,
PEG 33502000-6000 g;
B. 1000-2000 ml of pure water, 400-1200 ml of glycerol,
10-30 g of nano-silver micro powder and 20-50 g of sodium lauryl sulfate.
In the invention, the monomer carrier is a natural or synthetic high molecular gel material, the surfactant is an ionic surfactant and a nonionic surfactant, the dispersant is a high molecular polymer, a surfactant and an organic acid dispersant, and the transdermal enhancer is a natural or synthetic polymer and a synthetic elastic colloid.
The industrial production process of the nano-silver prostatitis antibacterial and anti-inflammatory gel comprises the steps of mixing and stirring pure water, glycerol and sodium lauryl sulfate uniformly according to the proportion, adding nano-silver micro powder and stirring uniformly, adding stearyl alcohol, PEG400 and PEG3350 under the conditions of heating and stirring at 60-70 ℃, finally mixing and homogenizing to be uniform, cooling to be solidified under stirring, and subpackaging.
The product of the invention can be used for treating prostatitis, and also has the effects of relieving symptoms and reducing pain of senile male organic prostate diseases. In addition, the product of the invention has extremely excellent antibacterial capacity, so the product has excellent curative effects of diminishing inflammation and relieving pain on internal and external hemorrhoids of a human body.
In the invention, the nano silver micro powder prepared by the nano silver micro powder which is applied by the inventor and has the application number of 01110767.7 and is named as anti-agglomeration broad-spectrum antibacterial nano silver micro powder is adopted.
The broad-spectrum antibacterial nano silver micro powder which is a product disclosed by the inventor in the patent application number 01110767.7 is adopted as the medicine material of the prostatitis antibacterial and anti-inflammatory gel. The silver particles carried on the micro powder have a particle size of 1-100 nm as detected by a scanning tunnel electron microscope, as shown in figure 4 (figures 1, 2 and 3 in the figures are not treated by an anti-aggregation technology), and the excellent performances of the antibacterial function display of the nano silver micro powder are shown in attached tables 1 and 2
Attached to Table 1, the microorganism is tested in the laboratory of the national liberated military medical testing center.
Attached Table 2, examined by Hill Hospital, Shanghai university of medical, in the bacterial laboratory.
The antibacterial mechanism of the present invention is as follows
Figure A0112950700051
From the above, it can be seen that nano-silver replaces-SH group in enzyme living in thallus with-SAg by the most classical antibacterial mechanism, so that enzyme loses activity to cause death of pathogenic bacteria, and the products are enzyme-2 SAg and H2And O, no secondary pathogenic factor exists.
In conclusion, the nano-silver prostatitis antibacterial and anti-inflammatory gel has excellent special functions due to the use of the nano-silver micro-powder as a medicine material. The antibacterial agent has remarkable antibacterial ability and wide antibacterial spectrum, and has obvious antibacterial functions on gram-positive bacteria, gram-negative bacteria, fungi and anaerobic bacteria. Especially, the bactericidal agent has bactericidal capacity on drug-resistant pathogenic bacteria, and has no toxicity, no allergy, no irritation and stronger hydrophilic performance and water bactericidal performance. Therefore, the product of the invention has quick effect, good curative effect and no toxic or side effect. The products of the invention may be administered rectally. The particle size of the nano-silver is 1-10 nanometers, the particle size of the silver particles is reduced, sothat the number of atoms on the surface layer is rapidly increased, the original coordination is insufficient, unsaturated bonds are exposed and increased, the surface energy of the atoms is increased, the chemical activity is extremely strong, and the nano-silver has good permeability and can penetrate through lipid layers wrapped outside human prostates and has excellent sterilization function. Meanwhile, the medicine also has the function of relieving the pain of patients on organic prostate diseases of old men, and also has excellent treatment function on internal and external hemorrhoids of human bodies.
The invention uses the anti-aggregation broad-spectrum antibacterial nano-silver micro-powder as a medicine, and the silver content of the medicine is 0.1-200 mg/g measured according to the methods of United States Pharmacopoeia (USP) and British Pharmacopoeia (BP).
The production process comprises the following auxiliary materials in percentage by weight:
pure water, glycerol, sodium lauryl sulfate, stearyl alcohol, polyethylene glycol (PEG) and the like (the monomer carrier in the process is natural and synthetic polymer gel material, preferably polyethylene glycol (PEG), which is a conventional additive sold on the market).
The active agent is ionic surfactant and nonionic surfactant, the dispersant is high molecular polymer, surfactant and organic acid, the active agent and dispersant are preferably sodium lauryl sulfate, the skin penetration enhancer is natural or synthetic polymer, synthetic elastic colloid, and preferably glycerol.
The above adjuvants or additives are commercially available, and further, similar products conventionally used in the industry may be used.
The technological process of the invention
The present invention is further illustrated by the following specific examples, which are intended to be illustrative only and not to limit the scope of the invention, wherein all parts and amounts are by weight based on total weight and "M" is molar.
Example 1:
according to application number 01110767.7, the name is: the example is only used for illustration and is not within the protection scope of the claims of the patent application.
The following liquid medicines (calculated according to 10 kg carrier)
A、AgNO3 0.5M，NH3·H2O 0.3M，NaOH 0.1M，
Adding water to the mixture until the total volume is 500 liters;
B. glucose 4M, HNO30.1M, boiling for 1-5 minutes, cooling, adding ethanol to make 10M, and the volume is 50 liters.
Cleaning carrier (medulla Junci), adding 98% medical alcohol and distilled water (ratio of 1: 15), immersing carrier, and vacuum extracting until the carrier is free of organic components and impurities.
Mixing 10 parts and 1 part of B (V/V) uniformly, standing for 10-40 minutes for impregnation, and adding 10 kg of treated carrier (rush). After dipping, pressurizing and homogenizing to mix the liquid medicine and the carrier evenly, adding a dispersant OP-10 continuously (under ventilation condition and proper stirring condition) in the chemical and physical treatment of the mixture in a reaction kettle until the rush is brownish yellow, and then cleaning, drying and crushing the mixture to obtain the aggregation-preventing broad-spectrum antibacterial nano silver micro powder.
Example 2
Calculated as 10 kg gel
Compounding agent:
a: 250 g of stearyl alcohol, 4005000 g of PEG, 33503000 g of PEG,
b: 1200 ml of pure water, 4 g of sodium lauryl sulfate, 550 ml of glycerol,
20 g of nano-silver micro powder;
the process comprises the following steps:
and (3) placing the preparation B into a heating and stirring reactor, stirring uniformly, heating to 60-65 ℃, adding the preparation A, keeping the temperature, stirring to uniformly mix, entering a mixing homogenizer, keeping the temperature, cooling to solidify under the stirring condition when the mixing and homogenizing are finished, and subpackaging.
Example 3
Calculated as 10 kg gel
Compounding agent:
a: 400 g of stearyl alcohol, 4500 g of PEG400, 33503000 g of PEG,
b: 1700 ml of pure water, 650 ml of glycerol, 4 g of sodium lauryl sulfate,
32 g of nano-silver micro powder;
the process comprises the following steps:
and (3) placing the preparation B into a heating and stirring reactor, stirring uniformly, heating to 60-65 ℃, adding the preparation A, keeping the temperature, stirring to uniformly mix, entering a mixing homogenizer, keeping the temperature, cooling to solidify under the stirring condition when the mixing and homogenizing are finished, and subpackaging.
Example 4
Calculated as 10 kg gel
Compounding agent:
a: 200 g of stearyl alcohol, 4003000 g of PEG, 33502500 g of PEG,
b: 1100 ml of pure water, 450 ml of glycerol, 4 g of sodium lauryl sulfate,
12 g of nano-silver micro powder;
the process was the same as in example 3.
Example 5
Calculated as 10 kg gel
Compounding agent:
a: 600 g of stearyl alcohol, 4007500 g of PEG, 33505500 g of PEG,
b: 1900 ml of pure water, 1150 ml of glycerol, 4 g of sodium lauryl sulfate,
28 g of nano-silver micro powder;
the process was the same as in example 3.
Example 6
Calculated as 10 kg gel
Compounding agent:
a: 500 g of stearyl alcohol, 4005500 g of PEG, 33503500 g of PEG,
b: 1600 ml of pure water, 850 ml of glycerol, 4 g of sodium lauryl sulfate,
25 g of nano-silver micro powder;
the process was the same as in example 3.
TABLE 1
Bacteriostatic results of PNSM and 8 antibacterial drugs
MIC method drug sensitive result of PNSM and antibacterial drug with original group bacteriostatic diameter (mm)
Bacterial name source washing negative benzene azole nitrogen benzyl cephalosporin cefazepam
Unwashed erythromycin
10 times and 100 times of penicillin G furazolidone oxime tacrolimus √ Staphylococcus aureus ATCC 25923181515724S S S S S S Escherichia coli ATCC 25922132710S S S S Pseudomonas aeruginosa ATCC 2785312121276S Clostridium perfringens CMCC (B) 6460610 Staphylococcus aureus (MRSA) secretion 17151576R R R R R R R Staphylococcus epidermidis (MRSE) secretion 18151676R R R R R R R R R S Streptococcus pyogenes secretion 98876S S S S S S S Neisseria gonorrhoeae secretion 101010731S S S S S S S S Escherichia coli secretion 17141476R R R R R R R enterobacter cloacae secretion 988711R R R R R R R R R enterobacter secretion 14121376R R R R R R R R R R R aeruginosa secretion Pseudomonas secretion 15151576R R R R R R stenotrophomonas maltophilia secretion 14131476R R R R S R S Acinetobacter baumannii secretion 131212719R R R S S Klebsiella pneumoniae secretion 15141476R R R S R S Serratia marcescens secretion 16131476R R R R R S Klebsiella Ferrosioides secretion 11101176R R R R R R R Klebsiella pneumoniae secretion 15131376R R S S Aeromonas hydrophila secretion 131113716R R S R S S Aeromonas sobria secretion 141212717R I S R S Vibrio vulnificus secretion 17151576R R R S S S S S S Proteus mirabilis secretion 11101079R R R S R Proteus secretion 1191176R R S R S R srr proteus pangami secretion 1091076R ri srr √ candida albicans secretion 21202076 candida albicans secretion 18171876 candida parapsilosis secretion 20192076 candida glabrata secretion 27262676 notes: s. sensitive I: an intermediate R: drug resistance
TABLE 2 Strain blank AB Fabric PNSM
20 times of no-washing of fabrics, 20 times of high-pressure no-washing and 20 times of high-pressure no-washing of 50 times of pseudomonas aeruginosa, 15131616 staphylococcus aureus, 15171515 escherichia coli, 13141815 MRSA, 14141715 bacillus cereus, 1113131515 vibrio vulnificus, 16161617 candida albicans, 21 11111111B group hemolytic streptococcus, 11111211 pseudomonas maltophilia, 12121514 nitrate negative bacillus, 14141315 salmonella paratyphi, 12, 12141914 salmonella alimentarius, 14141514 citrobacter, 14141513 pneumobacillus, 13131713 bacillus subtilis, 12121212 rhizogenes, 1012121212 alcaligenes faecalis, 14121616 pseudomonas stutzeri 12121413 Enterobacter cloacae-13131313 gonococcus-11111111
The results show that PNSM has inhibition effect on 20 strains of bacteria, and on bacteria which are easy to generate drug resistance, such as staphylococcus aureus drug-resistant strains (MRSA), pseudomonas aeruginosa, pseudomonas maltophilia, nitrate negative bacillus and the like, the inhibition effect on the bacteria is not obviously affected after high pressure and washing for 20 times and 50 times, and the bacteria cannot be inhibited after the AB fabric is washed for 20 times, so that the inhibition range of PNSM is wider than that of the AB fabric, and the inhibition effect cannot be affected by washing.

Claims (10)

1. The nano silver prostatitis antibacterial and anti-inflammatory gel is characterized by containing pharmaceutically acceptable additives and anti-aggregation broad-spectrum antibacterial nano silver micro powder, wherein the particle size of the nano silver is 1-100 nanometers, the surface layer is silver oxide of 2-8 nanometers, and the core is elemental silver.
2. The nano-silver prostatitis antibiotic and anti-inflammatory gel as claimed in claim 1, wherein the pharmaceutically acceptable additives include monomer carrier, surfactant, dispersant and transdermal enhancer.
3. The nano-silver prostatitis antibiotic and anti-inflammatory gel as claimed in claim 1 and 2, wherein the medicament formula is (based on 10 kg of gel):
A. 200 to 600 g of stearyl alcohol, 2000 to 8000 g of PEG400,
PEG 33502000-6000 g;
B. 1000-2000 ml of pure water, 400-1200 ml of glycerol,
10-30 g of nano-silver micro powder and 20-50 g of sodium lauryl sulfate.
4. The nano silver prostatitis antibiotic and anti-inflammatory gel as claimed in claim 1 and 2, wherein the monomer carrier is natural or synthetic high molecular gel material, preferably polyethylene glycol.
5. The nano-silver prostatitis antibiotic and anti-inflammatory gel as claimed in claim 1 or 2, wherein the surfactant is selected from ionic surfactant and nonionic surfactant, preferably sodium lauryl sulfate.
6. The nano silver prostatitis antibiotic and anti-inflammatory gel as claimed in claim 1 and 2, wherein the dispersant is a high molecular polymer, a surfactant and an organic acid dispersant, preferably sodium lauryl sulfate.
7. The nano-silver prostatitis antibiotic and anti-inflammatory gel as claimed in claim 1 or 2, wherein the transdermal enhancer is natural or synthetic polymer or synthetic elastomer, preferably glycerol.
8. The industrial production process of the nano-silver prostatitis antibacterial and anti-inflammatory gel as claimed in claim 1 to 3, wherein the pure water, the glycerol and the sodium lauryl sulfate are mixed and stirred uniformly according to the proportion, the nano-silver micro powder is added and stirred uniformly, the stearyl alcohol, the PEG400 and the PEG3350 are added under the conditions of heating and stirring at 60 to 70 ℃, finally, the mixture is mixed and homogenized to be uniform, and the mixture is cooled to be solidified under the stirring and subpackaged.
9. The application of the nano silver prostatitis antibacterial and anti-inflammatory gel as claimed in claim 1 to 3, which can be used as a medicament for treating human hemorrhoids.
10. The use of the nano-silver prostatitis antibacterial and anti-inflammatory gel as claimed in claim 1 to 3, which can be used for rectal administration to treat frequently encountered prostatitis in men and organic prostate diseases in elderly men.
CNB011295074A 2001-04-20 2001-06-22 Nanometer silver antimicrobial inflammation-relieving gel for curing prostatitis and its industrial production process Expired - Fee Related CN1169529C (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CNB011107677A CN1179646C (en) 2001-04-20 2001-04-20 Aggregation-preventing nanometer wide-spectrum antibacterial silve powder and its inductrial production process
CN01223000U CN2479952Y (en) 2001-04-20 2001-05-08 Nm silver plaster for trauma
CN01129505A CN1328819A (en) 2001-04-20 2001-06-22 Nanometer silver antimicrobial inflammation-relieving film for curing gynecopathy and its production process
CNB011295074A CN1169529C (en) 2001-04-20 2001-06-22 Nanometer silver antimicrobial inflammation-relieving gel for curing prostatitis and its industrial production process
CNB018231578A CN1224479C (en) 2001-04-20 2001-11-26 Mathod for preparing micro powder containing anti-agglomerated nanometer silver, micro powder produced by the mathod and its application
PCT/CN2001/001584 WO2002090025A1 (en) 2001-04-20 2001-11-26 Mathod for preparing micro powder containing anti-agglomerated nanometer silver, micro powder produced by the mathod and its application

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNB011107677A CN1179646C (en) 2001-04-20 2001-04-20 Aggregation-preventing nanometer wide-spectrum antibacterial silve powder and its inductrial production process
CN01223000U CN2479952Y (en) 2001-04-20 2001-05-08 Nm silver plaster for trauma
CN01129505A CN1328819A (en) 2001-04-20 2001-06-22 Nanometer silver antimicrobial inflammation-relieving film for curing gynecopathy and its production process
CNB011295074A CN1169529C (en) 2001-04-20 2001-06-22 Nanometer silver antimicrobial inflammation-relieving gel for curing prostatitis and its industrial production process

Publications (2)

Publication Number Publication Date
CN1328827A true CN1328827A (en) 2002-01-02
CN1169529C CN1169529C (en) 2004-10-06

Family

ID=27429906

Family Applications (5)

Application Number Title Priority Date Filing Date
CNB011107677A Expired - Fee Related CN1179646C (en) 2001-04-20 2001-04-20 Aggregation-preventing nanometer wide-spectrum antibacterial silve powder and its inductrial production process
CN01223000U Expired - Lifetime CN2479952Y (en) 2001-04-20 2001-05-08 Nm silver plaster for trauma
CN01129505A Pending CN1328819A (en) 2001-04-20 2001-06-22 Nanometer silver antimicrobial inflammation-relieving film for curing gynecopathy and its production process
CNB011295074A Expired - Fee Related CN1169529C (en) 2001-04-20 2001-06-22 Nanometer silver antimicrobial inflammation-relieving gel for curing prostatitis and its industrial production process
CNB018231578A Expired - Fee Related CN1224479C (en) 2001-04-20 2001-11-26 Mathod for preparing micro powder containing anti-agglomerated nanometer silver, micro powder produced by the mathod and its application

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CNB011107677A Expired - Fee Related CN1179646C (en) 2001-04-20 2001-04-20 Aggregation-preventing nanometer wide-spectrum antibacterial silve powder and its inductrial production process
CN01223000U Expired - Lifetime CN2479952Y (en) 2001-04-20 2001-05-08 Nm silver plaster for trauma
CN01129505A Pending CN1328819A (en) 2001-04-20 2001-06-22 Nanometer silver antimicrobial inflammation-relieving film for curing gynecopathy and its production process

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB018231578A Expired - Fee Related CN1224479C (en) 2001-04-20 2001-11-26 Mathod for preparing micro powder containing anti-agglomerated nanometer silver, micro powder produced by the mathod and its application

Country Status (2)

Country Link
CN (5) CN1179646C (en)
WO (1) WO2002090025A1 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6692773B2 (en) 2000-07-27 2004-02-17 Nucryst Pharmaceuticals Corp. Treatment of hyperproliferative skin disorders and diseases
US6719987B2 (en) 2000-04-17 2004-04-13 Nucryst Pharmaceuticals Corp. Antimicrobial bioabsorbable materials
US6723350B2 (en) 2001-04-23 2004-04-20 Nucryst Pharmaceuticals Corp. Lubricious coatings for substrates
US6989157B2 (en) 2000-07-27 2006-01-24 Nucryst Pharmaceuticals Corp. Dry powders of metal-containing compounds
US7001617B2 (en) 2001-04-23 2006-02-21 Nueryst Pharmaceuticals Corp. Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals
US7008647B2 (en) 2001-04-23 2006-03-07 Nucryst Pharmaceuticals Corp. Treatment of acne
US7137968B1 (en) 2000-03-13 2006-11-21 Nucryst Pharmaceuticals Corp. Transcutaneous medical device dressings and method of use
WO2007017901A2 (en) * 2005-06-08 2007-02-15 Khandelwal Sanjeev Silver nanoparticle dispersion formulation
US7201925B2 (en) 2002-04-23 2007-04-10 Nueryst Pharmaceuticals Corp. Treatment of ungual and subungual diseases
US7255881B2 (en) 2000-07-27 2007-08-14 Nucryst Pharmaceuticals Corp. Metal-containing materials
US7427416B2 (en) 2000-07-27 2008-09-23 Nucryst Pharmaceuticals Corp. Methods of treating conditions using metal-containing materials
US7470437B2 (en) 2000-07-27 2008-12-30 Nucryst Pharmaceuticals Corp. Methods of treating conditions with a metal-containing material
US8865227B2 (en) 2007-12-20 2014-10-21 Smith & Nephew (Overseas) Limited Metal carbonate particles and methods of making thereof
CN105640986A (en) * 2014-11-28 2016-06-08 广东工业大学 Silver nanoparticle composition for control of lung cancer and prostate cancer
CN113664213A (en) * 2021-08-04 2021-11-19 湖南伟方生命科技有限公司 Preparation method and application of nano-silver antibacterial liquid
CN114028318A (en) * 2021-10-14 2022-02-11 湖南伟方生命科技有限公司 Male antibacterial liquid and preparation method and application thereof

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002315728A1 (en) * 2002-06-03 2003-12-19 Shenzhen Tsinghua Yuanxing Nano-Material Co., Ltd. Composite nanostuctured silver
DE10346387A1 (en) * 2003-10-07 2005-06-09 Henkel Kgaa Antimicrobial equipment of bathroom and toilet articles
EP1616926A1 (en) * 2004-07-15 2006-01-18 Interuniversitair Microelektronica Centrum ( Imec) Slurry composition and method for chemical polishing of copper integrated with tungsten based barrier metals
US8399027B2 (en) 2005-04-14 2013-03-19 3M Innovative Properties Company Silver coatings and methods of manufacture
CN100386369C (en) * 2005-06-03 2008-05-07 陈汝霖 New type products of Nano silver latex, and preparation method
US20070166399A1 (en) 2006-01-13 2007-07-19 3M Innovative Properties Company Silver-containing antimicrobial articles and methods of manufacture
CN101466388A (en) * 2006-06-16 2009-06-24 默克专利股份有限公司 Antimicrobial carbon
CN100457084C (en) * 2006-08-04 2009-02-04 武汉正午阳光医药生物科技有限公司 Nanometer silver type external use antibiotic gel for female external use and its prepn. method
CN100396290C (en) * 2006-11-03 2008-06-25 段炬红 External use anti-bacteria foaming agent for gynecology
CN101049279B (en) * 2007-04-30 2010-06-23 东莞市拓扑光电科技有限公司 Antibacterial shampoo of Nano silver, and preparation method
US8815307B2 (en) * 2008-12-31 2014-08-26 Colotex Industrial Co., Ltd. Process for producing porous polymer masterbatch and fiber thereof having anti-bacterial and odor eliminating functions
CN102430761A (en) * 2011-12-12 2012-05-02 池州学院 Preparation method for water-soluble nano silver for killing oncomelania hupensis
CN103341642B (en) * 2013-07-26 2015-12-02 莆田学院 A kind of cellulose green syt method of nano silver particles
CN103688996B (en) * 2013-11-28 2014-12-10 太原理工大学 Method for preparing silver-loaded antibacterial agent by using waste cotton fiber
CN107598186B (en) * 2017-08-30 2019-08-20 苏州工业园区格云环保新材料有限公司 A kind of preparation method of nano silver and its fumigation liquid
CN109137490A (en) * 2018-06-27 2019-01-04 苏州市天翱特种织绣有限公司 A kind of antibacterial modified method of cotton fiber
MX2021009408A (en) 2019-02-05 2021-11-12 Griffith Foods Int Inc Anti-caking agent or flow agent for a seasoning, pharmaceuticals or nutraceuticals.
CN111763365B (en) * 2020-07-17 2022-09-02 安信纳米生物科技（珠海）有限公司 Antibacterial fresh-keeping material containing nano-silver and preparation method thereof
CN115137681A (en) * 2022-06-23 2022-10-04 深圳市黄田荔枝品牌发展有限公司 Litchi mask and preparation method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07173022A (en) * 1993-12-17 1995-07-11 Asahi Chem Ind Co Ltd Antimicrobial agent
CN1058868C (en) * 1994-11-26 2000-11-29 广州安信生物科技发展有限公司 Long-effect and broad-spectrum antibiotic granules and its production
JP4025839B2 (en) * 1996-09-12 2007-12-26 Ｄｏｗａエレクトロニクス株式会社 Silver powder and method for producing silver powder
CN1161511C (en) * 1999-07-27 2004-08-11 蒋建华 Long-acting wide-spectrum antiseptic nanometer silver fabric and its making method
CN1266761A (en) * 2000-03-23 2000-09-20 南京大学 Process for preparing nm-class silver powder

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7137968B1 (en) 2000-03-13 2006-11-21 Nucryst Pharmaceuticals Corp. Transcutaneous medical device dressings and method of use
US6719987B2 (en) 2000-04-17 2004-04-13 Nucryst Pharmaceuticals Corp. Antimicrobial bioabsorbable materials
US7470437B2 (en) 2000-07-27 2008-12-30 Nucryst Pharmaceuticals Corp. Methods of treating conditions with a metal-containing material
US7255881B2 (en) 2000-07-27 2007-08-14 Nucryst Pharmaceuticals Corp. Metal-containing materials
US6692773B2 (en) 2000-07-27 2004-02-17 Nucryst Pharmaceuticals Corp. Treatment of hyperproliferative skin disorders and diseases
US6989157B2 (en) 2000-07-27 2006-01-24 Nucryst Pharmaceuticals Corp. Dry powders of metal-containing compounds
US7427416B2 (en) 2000-07-27 2008-09-23 Nucryst Pharmaceuticals Corp. Methods of treating conditions using metal-containing materials
US7008647B2 (en) 2001-04-23 2006-03-07 Nucryst Pharmaceuticals Corp. Treatment of acne
US6939568B2 (en) 2001-04-23 2005-09-06 Nucryst Pharmaceuticals Corp. Treatment of inflammatory skin conditions
US6723350B2 (en) 2001-04-23 2004-04-20 Nucryst Pharmaceuticals Corp. Lubricious coatings for substrates
US6989156B2 (en) 2001-04-23 2006-01-24 Nucryst Pharmaceuticals Corp. Therapeutic treatments using the direct application of antimicrobial metal compositions
US7087249B2 (en) 2001-04-23 2006-08-08 Nucryst Pharmaceuticals Corp. Treatment of mucosal membranes
US7001617B2 (en) 2001-04-23 2006-02-21 Nueryst Pharmaceuticals Corp. Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals
US7201925B2 (en) 2002-04-23 2007-04-10 Nueryst Pharmaceuticals Corp. Treatment of ungual and subungual diseases
WO2007017901A3 (en) * 2005-06-08 2007-06-14 Khandelwal Sanjeev Silver nanoparticle dispersion formulation
WO2007017901A2 (en) * 2005-06-08 2007-02-15 Khandelwal Sanjeev Silver nanoparticle dispersion formulation
US8865227B2 (en) 2007-12-20 2014-10-21 Smith & Nephew (Overseas) Limited Metal carbonate particles and methods of making thereof
CN105640986A (en) * 2014-11-28 2016-06-08 广东工业大学 Silver nanoparticle composition for control of lung cancer and prostate cancer
CN113664213A (en) * 2021-08-04 2021-11-19 湖南伟方生命科技有限公司 Preparation method and application of nano-silver antibacterial liquid
CN114028318A (en) * 2021-10-14 2022-02-11 湖南伟方生命科技有限公司 Male antibacterial liquid and preparation method and application thereof
CN114028318B (en) * 2021-10-14 2023-11-21 湖南伟方生命科技有限公司 Male antibacterial liquid and preparation method and application thereof

Also Published As

Publication number Publication date
CN1179646C (en) 2004-12-15
CN1322474A (en) 2001-11-21
CN1169529C (en) 2004-10-06
CN2479952Y (en) 2002-03-06
CN1505551A (en) 2004-06-16
WO2002090025A1 (en) 2002-11-14
CN1224479C (en) 2005-10-26
CN1328819A (en) 2002-01-02

Similar Documents

Publication Publication Date Title
CN1328827A (en) Nanometer silver antimicrobial inflammation-relieving gel for curing prostatitis and its industrial production process
Ran et al. Hyaluronic acid-templated Ag nanoparticles/graphene oxide composites for synergistic therapy of bacteria infection
El-Ela et al. New approach in ulcer prevention and wound healing treatment using doxycycline and amoxicillin/LDH Nanocomposites
CN1161511C (en) Long-acting wide-spectrum antiseptic nanometer silver fabric and its making method
CN101999412A (en) Nano-silver solution and preparation method thereof
CN1147640C (en) Antibacterial fabric containing nm-class silver powder and its making method
Sun et al. Phytochemical-encapsulated nanoplatform for “on-demand” synergistic treatment of multidrug-resistant bacteria
AU2001240358A1 (en) Bactericidal preparation
CN1183285C (en) Aggregation-preventing wide-spectrum nanometer antibiotic silver yarn and its industrial production process
CN1672689A (en) Nano silver antiseptic gel for treating women's genital tract infection and its prepn and application
CN1369206A (en) Nano Silver sterilizing gel, its preparing method and use
CN1843124A (en) Nano silver coating agent for sterilization and its preparation method
CN1943593A (en) External use anti-bacteria foaming agent for gynecology
Samrat et al. Evaluation of improved antifungal activity of fluconazole–silver nanoconjugate against pathogenic fungi
Islamov et al. New antituberculosis drug FS-1
CN1259919C (en) Sterilizing and bacteria inhibiting pharmaceutical composition and its formulation and preparation process
CN1206990C (en) Liquid preparation containing norfloxacin and metronidazole
CN1307881C (en) New use of bactericide H4Ag 206 containing silver and its prepared medicine
CN103110976A (en) Skin antimicrobial gel recipe and preparation method thereof
CN105380900B (en) A kind of nano magnetic therapy external-use gel for treating acne and its preparation method and application
CN1335426A (en) Aggregation-preventing wide-spectrum antiseptic nanometer silver knitted article and fabric and their industrial production process
CN1286525C (en) New type pellicle of ocean lysozyme and preparation method
US11883542B1 (en) Chitosan film with ternary metal oxides
US11957797B1 (en) Chitosan film with ternary metal oxides
CA2780785A1 (en) Pharmaceutical composition having antimicrobial and anti-inflammatory activity for parenteral administration, process for preparing same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Free format text: FORMER OWNER: ZHU LI

Effective date: 20050225

Owner name: TSINGHUA YUANXING BIO-PHARM TECHNOLOGY CO., LTD.

Free format text: FORMER OWNER: ZHU HONGJUN

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20050225

Address after: 518057, Shenzhen hi tech Development Zone, North District, Nanshan District Road

Patentee after: Tsinghua Yuanxing Biomedicine Tech Co., Ltd., Shenzhen

Address before: Changning District Shanghai Fahuazhen 200000 No. 236

Co-patentee before: Zhu Chi

Patentee before: Zhu Hongjun

C57 Notification of unclear or unknown address
DD01 Delivery of document by public notice

Addressee: Wang Lingjiang

Document name: Special business review memo

C56 Change in the name or address of the patentee

Owner name: SHENZHEN YUANXING BIO-PHARM CO., LTD.

Free format text: FORMER NAME: TSINGHUA YUANXING BIOMEDICINE TECH CO., LTD., SHENZHEN

CP03 Change of name, title or address

Address after: 518057 Lang Shan Road, North District, Nanshan District hi tech Development Zone, Guangdong, Shenzhen

Patentee after: Shenzhen Yuanxing Bio-Pharm Co., Ltd.

Address before: 518057, Shenzhen hi tech Development Zone, North District, Nanshan District Road

Patentee before: Tsinghua Yuanxing Biomedicine Tech Co., Ltd., Shenzhen

DD01 Delivery of document by public notice

Addressee: Wang Lingjiang

Document name: Notification of Passing Examination on Formalities

ASS Succession or assignment of patent right

Owner name: SHENZHEN YUANXING NANO-PHARMA CO.,LTD.

Free format text: FORMER OWNER: SHENZHEN YUANXING BIO-PHARM CO., LTD.

Effective date: 20150909

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20150909

Address after: 518000 Guangdong city of Shenzhen province Nanshan District high tech Industrial Park, North Central Avenue, North Song Ping Road No. 1 Lite technology building south 10 layer 1001

Patentee after: Shenzhen Yuanxing Nano-Pharmaceutical Co., Ltd.

Address before: 518057 Lang Shan Road, North District, Nanshan District hi tech Development Zone, Guangdong, Shenzhen

Patentee before: Shenzhen Yuanxing Bio-Pharm Co., Ltd.

DD01 Delivery of document by public notice

Addressee: Wang Lingjiang

Document name: Notification of Passing Examination on Formalities

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20041006

Termination date: 20160622